The National Health Council (NHC) has been actively involved in the Medicare Drug Price Negotiation Program (MDPNP) since its inception, particularly focused on building patient engagement opportunities to ensure the patient’s perspective in negotiations. The NHC supports member education and engagement each cycle and provides feedback to the Centers for Medicare and Medicaid Services (CMS).
MDPNP Resources
IPAY 2028: Supporting Effective Engagement in the Medicare Drug Negotiation Program (MDNP)
Amplifying the Patient Voice: Reflections and Recommendations from the Second Cycle of CMS Patient Engagement
The National Health Council (NHC) held a roundtable discussion on June 30, 2025, with members of the patient advocacy community to reflect on and enhance opportunities for patient input at the Centers for Medicare and Medicaid Services (CMS). The discussion specifically focused on CMS’ patient engagement activities during the second cycle of the Medicare Drug Price Negotiation Program (MDPNP), undertaken in April 2025. Established by the Inflation Reduction Act of 2022 (IRA), MDPNP allows for negotiation between the government and manufacturers on the pricing of CMS-selected drugs for Medicare Part B and D. The number of drugs selected for negotiation increases annually; in this second cycle, 15 drugs were selected, up from 10 in 2024.
Read the report here.
